Search

Displaying results 791 - 800 of 8468 in total
  1. Drug

    Linaclotide

    go.drugbank.com/drugs/DB08890
    ApprovedInvestigational

    Linaclotide was first approved by the FDA on August 30, 2012.[A260271] It gained EMA and Health Canada approval on November 26, 2012 [L47216] and December 3, 2013,[L47221] respectively.

  2. Drug

    Cannabidiol

    go.drugbank.com/drugs/DB09061
    ApprovedInvestigational

    Epidiolex was granted Orphan Drug designation as well as Fast Track Approval from the FDA for further study in these hard to treat conditions. … CBD is currently available in Canada within a 1:1 formulation with tetrahydrocannbinol (THC) (as the formulation known as "nabiximols") as the brand name product Sativex.

  3. Drug

    Drometrizole trisiloxane

    go.drugbank.com/drugs/DB11585
    Approved

    being generally recognized as safe and effective for over-the-counter sunscreen use [L2795, F82]. … The compound is a lipophilic benzotriazole derivative marketed as Meroxyl XL by L'Oreal, although sunscreens with drometrizole trisiloxane are currently only approved for use in the EU, Canada, Australia

    Mixtures: Kiehls Since 1851 Dermatologist Solutions Ultra Light Daily UV Defense Tone Up SPF 50 PA Plus Plus Plus Plus Antipollution, Airyday Spf50+ Clear As Day Dreamscreen
  4. Drug

    Naloxone

    go.drugbank.com/drugs/DB01183
    ApprovedInvestigationalVet approved

    [A234594] More specifically, naloxone has a high affinity for μ-opioid receptors, where it acts as an inverse agonist, causing the rapid removal of any other drugs bound to these receptors. … [L33714,L33719] The primary purpose of including naloxone within Suboxone is to act as a deterrent to injection, as injected naloxone would rapidly reverse the effects of buprenorphine.

    Mixtures: PMS-buprenorphine-naloxone, PMS-buprenorphine-naloxone
  5. Drug

    Osimertinib

    go.drugbank.com/drugs/DB09330
    ApprovedInvestigational

    [A7928] Development of third-generation EGFR-TKIs, such as osimertinib, has been in response to altered tumour resistance patterns following treatment and toxic side effects that impact patient quality … testing and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor.

  6. Drug

    Glycyrrhizic acid

    go.drugbank.com/drugs/DB13751
    ApprovedInvestigational

    [A33062] From January 2014, glycyrrhizic acid as part of the licorice extract was approved by the FDA as an existing food sweetener. … [T204] Glycyrrhizic acid has been developed in Japan and China as a hepatoprotective drug in cases of chronic hepatitis.

  7. Indication

    Periarteritis nodosa

    go.drugbank.com/conditions/DBCOND0023002
    Drugs: Tetracosactide
    Synonyms: PAN - Polyarteritis nodosa
  8. Drug

    Adagrasib

    go.drugbank.com/drugs/DB15568
    ApprovedInvestigational

    [A254941] However, the development of KRAS inhibitors has been challenging due to their high affinity for guanosine triphosphate (GTP) and guanosine diphosphate (GDP), as well as the lack of a clear binding … KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations.

    Categories: RAS GTPase Inhibitors
  9. Drug

    Selenium

    go.drugbank.com/drugs/DB11135
    ApprovedInvestigationalVet approved

    Selenium is a trace metal in the human body particularly important as a component of glutathione peroxidase, an important enzyme in the prevention of cellular damage by free radicals and reactive oxygen

    Mixtures: Swiss One Multi Vit & Chel Min Tab, Vege Swiss One Multivitamin W Chel Mins Tab
  10. Drug

    Mepyramine

    go.drugbank.com/drugs/DB06691
    ApprovedVet approved

    However, it rapidly permeates the brain and so often causes drowsiness as a side effect. … It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescription medication used for cough, cold, or allergic conditions.

    Mixtures: Midol Pms, Midol Pms